title: Lipid profile during pregnancy in HIV-infected women.
abstract: OBJECTIVE
  We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study.
  
  
  METHODS
  Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal changes and differences in lipid values at each trimester by protease inhibitors (PIs) and stavudine use. Multivariate analyses were used to control for simultaneous factors potentially leading to hyperlipidemia. Study population included 248 women.
  
  
  RESULTS
  Lipid values increased progressively and significantly during pregnancy: mean increases between the first and third trimesters were 141.6 mg/dL for triglycerides (p < .001), 60.8 mg/dL for total cholesterol (p < .001), 13.7 mg/dL for HDL cholesterol (p < .001), and 17.8 mg/dL for LDL cholesterol (p = .001). At all trimesters, women on PIs had significantly higher triglyceride values compared to women not on PIs. The effect of PIs on cholesterol levels was less consistent. Stavudine showed a dyslipidemic effect at first trimester only. Multivariate analyses confirmed these observations and suggested a potential role of other cofactors in the development of hyperlipidemia during pregnancy.
  
  
  CONCLUSIONS
  The changes observed point to the need to further explore the causes and the clinical correlates of hyperlipidemia during pregnancy in women with HIV.
authors.affiliation: Department of Drug Research and Evaluation, Istituto Superiore di Sanità, Rome. floridia@iss.it
authors.forename: M
authors.initials: M
authors.lastname: Floridia
authors.forename: E
authors.initials: E
authors.lastname: Tamburrini
authors.forename: M
authors.initials: M
authors.lastname: Ravizza
authors.forename: C
authors.initials: C
authors.lastname: Tibaldi
authors.forename: M F
authors.initials: MF
authors.lastname: Ravagni Probizer
authors.forename: G
authors.initials: G
authors.lastname: Anzidei
authors.forename: M
authors.initials: M
authors.lastname: Sansone
authors.forename: F
authors.initials: F
authors.lastname: Mori
authors.forename: E
authors.initials: E
authors.lastname: Rubino
authors.forename: M
authors.initials: M
authors.lastname: Meli
authors.forename: S
authors.initials: S
authors.lastname: Dalzero
authors.forename: G
authors.initials: G
authors.lastname: Guaraldi
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood; D007558:Italy; D050356:Lipid Metabolism / Q000187:drug effects; D016015:Logistic Models; D011159:Population Surveillance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood*; D011264:Pregnancy Trimesters / Q000097:blood; D018119:Stavudine / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D017320:HIV Protease Inhibitors; D014280:Triglycerides; D018119:Stavudine